Literature DB >> 12219874

Enhanced thromboxane synthesis during chronic reductions in uterine perfusion pressure in pregnant rats.

Maria T Llinás1, Barbara T Alexander, Mona Seedek, Sean R Abram, Anna Crell, Joey P Granger.   

Abstract

BACKGROUND: The purpose of this study was to determine the role of thromboxane A2 (TXA2) in a conscious, chronically instrumented rat model of pregnancy-induced hypertension (PIH) produced by chronic reductions in uterine perfusion pressure (RUPP).
METHODS: Mean arterial pressure (MAP), glomerular filtration rate (GFR), effective renal plasma flow (ERPF) and 24-h urinary excretion of TXB2 (metabolite of TXA2) were determined in normal pregnant rats and RUPP pregnant rats.
RESULTS: At day 20 of pregnancy, RUPP rats showed a significantly (P < .05) higher MAP (125 +/- 3 mm Hg v 100 +/- 2 mm Hg) as compared with normal pregnant controls. The elevation in arterial pressure in RUPP group was associated with a marked increase (P < .05) in the urinary concentration of TXB2 compared with normal pregnant group (3663 +/- 488 v 2646 +/- 257 pg/24 h). Baseline GFR (1.74 +/- 0.13 v 2.40 +/- 0.20 mL/min, respectively, P < .05) and ERPF (5.13 +/- 0.44 v 6.44 +/- 0.58 mL/min, respectively) were decreased in RUPP rats relative to pregnant controls. Infusion of a TX receptor antagonist, SQ 29,548 (2 mg/kg bolus plus 2 mg/kg per h infusion) had no significant effect on increased MAP in RUPP pregnant rats. Similarly, ERPF and GFR did not change during acute blockade of TXA2 receptors in this group.
CONCLUSION: These findings suggest that enhanced production of TXA2 does not play a major role in mediating the hypertension and renal vasoconstriction produced by chronic RUPP in pregnant rats.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12219874     DOI: 10.1016/s0895-7061(02)02975-8

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  15 in total

1.  Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2012-08

2.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2010-04

Review 3.  Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia.

Authors:  Babbette D LaMarca; Jeffery Gilbert; Joey P Granger
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

Review 4.  A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model.

Authors:  Jing Li; Babbette LaMarca; Jane F Reckelhoff
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-20       Impact factor: 4.733

Review 5.  Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Dania A Shah; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2015-04-24       Impact factor: 5.858

6.  Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia.

Authors:  Florian Herse; Babbette Lamarca; Carl A Hubel; Tea Kaartokallio; A Inkeri Lokki; Eeva Ekholm; Hannele Laivuori; Martin Gauster; Berthold Huppertz; Meryam Sugulle; Michael J Ryan; Sarah Novotny; Justin Brewer; Joon-Keun Park; Michael Kacik; Joachim Hoyer; Stefan Verlohren; Gerd Wallukat; Michael Rothe; Friedrich C Luft; Dominik N Muller; Wolf-Hagen Schunck; Anne C Staff; Ralf Dechend
Journal:  Circulation       Date:  2012-11-15       Impact factor: 29.690

7.  Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia.

Authors:  J S Possomato-Vieira; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-06-14

8.  Biopolymer-Delivered, Maternally Sequestered NF-κB (Nuclear Factor-κB) Inhibitory Peptide for Treatment of Preeclampsia.

Authors:  Adrian C Eddy; John Aaron Howell; Heather Chapman; Erin Taylor; Fakhri Mahdi; Eric M George; Gene L Bidwell
Journal:  Hypertension       Date:  2019-12-02       Impact factor: 10.190

Review 9.  Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy.

Authors:  Stephanie J Sheppard; Raouf A Khalil
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2010-03

Review 10.  Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin?

Authors:  Babbette D LaMarca; Barbara T Alexander; Jeffery S Gilbert; Michael J Ryan; Mona Sedeek; Sydney R Murphy; Joey P Granger
Journal:  Gend Med       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.